Straumann AGM: shareholders approve all proposals of the Board of Directors 

  • Annual Report approved; consent on Compensation Report
  • All Directors re-elected
  • Dividend of CHF 3.75 per share approved (dividend yield: 2.9%)

 

Basel, 5 April 2013: At Straumann’s Annual General Meeting (AGM) in Basel today, the shareholders approved all the proposals put forward by the Board of Directors. 490 shareholders attended the meeting and a total of 7 795 121 voting shares were represented, corresponding to 50% of the overall share capital.

 

Annual Report approved; consent for Compensation Report

The shareholders approved the 2012 Annual Report, the 2012 Financial Statements and the discharge of the Board of Directors for their activities in 2012. In an advisory vote, they also consented to the 2012 Compensation Report. PricewaterhouseCoopers of Basel was reappointed as Statutory Auditors and Group Auditors for a further term of one year.

 

Board of Directors re-elected

All the Directors of the Straumann Board – Gilbert Achermann, Dr Sebastian Burckhardt, Dominik Ellenrieder, Roland Hess, Ulrich Looser, Dr Beat Lüthi, Stefan Meister and Dr h.c. Thomas Straumann – were re-elected for a further one-year term of office. The Board convened after the AGM and reappointed Gilbert Achermann as its Chairman and Thomas Straumann as Vice Chairman.

 

Stable dividend

The meeting approved the appropriation of the available earnings. CHF 57.9 million were allocated to the 2012 dividend. With CHF 3.75 per share, Straumann is maintaining the same payout as in previous years, resulting in a dividend yield of 2.9%. The payout will be made as of 12 April 2013.

 

2014 AGM

The next ordinary general meeting of Straumann’s shareholders will be convened on 11 April 2014 at the Basel Congress Center.

 

 

About Straumann

Headquartered in Basel, Switzerland, Straumann (SIX: STMN) is a global leader in implant, restorative and regenerative dentistry. In collaboration with leading clinics, research institutes and universities, Straumann researches, develops and manufactures dental implants, instruments, prosthetics and tissue regeneration products for use in tooth replacement and restoration solutions or to prevent tooth loss. Straumann currently employs approximately 2500 people worldwide and its products and services are available in more than 70 countries through its broad network of distribution subsidiaries and partners.